Inhalation Sciences: Breathing New Life into Respiratory Research
May 28, 2025, 10:14 am
Location: Sweden, Huddinge
Employees: 11-50
Founded date: 2005
Total raised: $1.47M
Inhalation Sciences AB (ISAB) is making waves in the world of respiratory research. The company, based in Sweden, is on a mission to transform how inhalation studies are conducted. With its innovative technologies, ISAB is poised to reshape the landscape of drug development and regulatory compliance.
The recent partnership with BioLum Sciences, a U.S.-based company, marks a significant milestone for ISAB. This collaboration is not just a handshake; it’s a strategic alliance aimed at expanding ISAB’s footprint in the U.S. market. The agreement allows ISAB to leverage BioLum’s established network and expertise in inhalation diagnostics. Together, they aim to meet the rising demand for advanced in vitro models, especially in light of new FDA guidelines.
The FDA has been tightening its grip on regulatory standards. Researchers are now under pressure to adopt more precise and ethical methods. ISAB’s technologies, PreciseInhale® and DissolvIt®, are at the forefront of this shift. They offer researchers the tools to make informed decisions early in the drug development process. This is a game-changer, as it saves time and resources while adhering to stringent regulatory requirements.
BioLum Sciences, based in Dallas, Texas, specializes in oxidative stress markers and inhalation diagnostics. Their expertise complements ISAB’s offerings, creating a powerful synergy. This partnership is like a bridge connecting two innovative minds, ready to tackle the challenges of respiratory research head-on.
The collaboration comes at a crucial time. ISAB’s recent annual report for 2024 reveals a year of mixed results. While interest in their services remains strong, financial challenges have hampered growth. The company reported a decline in net sales, dropping from SEK 17.5 million in 2023 to SEK 11 million in 2024. Operating losses also widened, raising concerns about the company’s financial health.
However, the outlook for 2025 is more optimistic. The CEO of ISAB, Manoush Masarrat, expressed confidence in the company’s ability to rebound. With a pipeline of outstanding quotes valued at approximately SEK 45 million, there’s potential for recovery. The partnership with BioLum is expected to enhance ISAB’s market presence and drive sales.
The FDA’s approval of the study report for the DissolvIt® module is another feather in ISAB’s cap. This breakthrough confirms the technology’s commercial viability and opens doors for new customer projects. It’s a validation that could attract more clients seeking reliable in vitro solutions.
ISAB is not resting on its laurels. The company plans to launch an upgraded version of its XposeAli module, now featuring Microperfusion. This enhancement addresses a critical gap in the market, catering to biological customers who have long awaited such a solution. By diversifying its offerings, ISAB aims to solidify its position as a leader in the field of inhalation research.
The financial landscape remains challenging. Operating expenses have been trimmed in response to declining revenues. As of December 2024, ISAB’s cash reserves stood at SEK 4.4 million, down from SEK 7.8 million the previous year. To bolster its financial position, the company is planning a rights issue of approximately SEK 15 million. This move is designed to accelerate market initiatives and capitalize on the growing demand for its services.
Despite the hurdles, ISAB is committed to innovation. The company is actively engaging with potential partners for the clinical application of its PreciseInhale platform. This proactive approach could lead to new collaborations and expanded market opportunities.
The partnership with BioLum is just the beginning. ISAB is also exploring collaborations with other companies to enhance its service portfolio. The strategic partnership with Actarmo Medical GmbH, announced earlier in 2024, is another step toward expanding ISAB’s capabilities. This collaboration broadens ISAB’s market potential by 30%, tapping into a total addressable market of approximately EUR 630 million.
Inhalation Sciences is navigating a complex landscape. The demand for advanced inhalation research tools is growing, driven by regulatory changes and a push for more ethical research practices. ISAB’s technologies are well-positioned to meet this demand. As the company strengthens its U.S. presence and expands its offerings, it is set to play a pivotal role in the future of respiratory research.
In conclusion, Inhalation Sciences is at a crossroads. The partnership with BioLum Sciences opens new avenues for growth and innovation. While financial challenges loom, the company’s commitment to advancing inhalation research remains unwavering. With strategic partnerships and a focus on cutting-edge technology, ISAB is breathing new life into the world of respiratory research. The future looks promising, and the journey has just begun.
The recent partnership with BioLum Sciences, a U.S.-based company, marks a significant milestone for ISAB. This collaboration is not just a handshake; it’s a strategic alliance aimed at expanding ISAB’s footprint in the U.S. market. The agreement allows ISAB to leverage BioLum’s established network and expertise in inhalation diagnostics. Together, they aim to meet the rising demand for advanced in vitro models, especially in light of new FDA guidelines.
The FDA has been tightening its grip on regulatory standards. Researchers are now under pressure to adopt more precise and ethical methods. ISAB’s technologies, PreciseInhale® and DissolvIt®, are at the forefront of this shift. They offer researchers the tools to make informed decisions early in the drug development process. This is a game-changer, as it saves time and resources while adhering to stringent regulatory requirements.
BioLum Sciences, based in Dallas, Texas, specializes in oxidative stress markers and inhalation diagnostics. Their expertise complements ISAB’s offerings, creating a powerful synergy. This partnership is like a bridge connecting two innovative minds, ready to tackle the challenges of respiratory research head-on.
The collaboration comes at a crucial time. ISAB’s recent annual report for 2024 reveals a year of mixed results. While interest in their services remains strong, financial challenges have hampered growth. The company reported a decline in net sales, dropping from SEK 17.5 million in 2023 to SEK 11 million in 2024. Operating losses also widened, raising concerns about the company’s financial health.
However, the outlook for 2025 is more optimistic. The CEO of ISAB, Manoush Masarrat, expressed confidence in the company’s ability to rebound. With a pipeline of outstanding quotes valued at approximately SEK 45 million, there’s potential for recovery. The partnership with BioLum is expected to enhance ISAB’s market presence and drive sales.
The FDA’s approval of the study report for the DissolvIt® module is another feather in ISAB’s cap. This breakthrough confirms the technology’s commercial viability and opens doors for new customer projects. It’s a validation that could attract more clients seeking reliable in vitro solutions.
ISAB is not resting on its laurels. The company plans to launch an upgraded version of its XposeAli module, now featuring Microperfusion. This enhancement addresses a critical gap in the market, catering to biological customers who have long awaited such a solution. By diversifying its offerings, ISAB aims to solidify its position as a leader in the field of inhalation research.
The financial landscape remains challenging. Operating expenses have been trimmed in response to declining revenues. As of December 2024, ISAB’s cash reserves stood at SEK 4.4 million, down from SEK 7.8 million the previous year. To bolster its financial position, the company is planning a rights issue of approximately SEK 15 million. This move is designed to accelerate market initiatives and capitalize on the growing demand for its services.
Despite the hurdles, ISAB is committed to innovation. The company is actively engaging with potential partners for the clinical application of its PreciseInhale platform. This proactive approach could lead to new collaborations and expanded market opportunities.
The partnership with BioLum is just the beginning. ISAB is also exploring collaborations with other companies to enhance its service portfolio. The strategic partnership with Actarmo Medical GmbH, announced earlier in 2024, is another step toward expanding ISAB’s capabilities. This collaboration broadens ISAB’s market potential by 30%, tapping into a total addressable market of approximately EUR 630 million.
Inhalation Sciences is navigating a complex landscape. The demand for advanced inhalation research tools is growing, driven by regulatory changes and a push for more ethical research practices. ISAB’s technologies are well-positioned to meet this demand. As the company strengthens its U.S. presence and expands its offerings, it is set to play a pivotal role in the future of respiratory research.
In conclusion, Inhalation Sciences is at a crossroads. The partnership with BioLum Sciences opens new avenues for growth and innovation. While financial challenges loom, the company’s commitment to advancing inhalation research remains unwavering. With strategic partnerships and a focus on cutting-edge technology, ISAB is breathing new life into the world of respiratory research. The future looks promising, and the journey has just begun.